Icagen, Inc.

Seth V. Hetherington, M.D., senior vice president of Clinical and Regulatory Affairs at Icagen, Inc., will be leaving the company at the end of the year. Greg C. Rigdon, Ph.D., vice president, New Product Development, will assume Dr. Hetherington’s role, taking on responsibility for the company’s clinical development efforts.

P. Kay Wagoner, chief executive officer of Icagen, said, “Dr. Hetherington has provided outstanding leadership to Icagen’s clinical development efforts over the past four years. While we are of course disappointed, we understand his decision to return to his background in the area of infectious diseases. We thank him for his outstanding service to Icagen and wish him all the best in his future endeavors.”

Dr. Wagoner continued, “Our progress in completing our submission to the FDA in support of the clinical development of ICA-105665 remains on track. Dr. Rigdon, who will assume leadership of the clinical effort, has been deeply involved in our epilepsy and pain program since its inception. We are confident that there will be no loss of continuity in our epilepsy and pain program as a result of these management changes.”

Prior to joining the company, Dr. Rigdon spent ten years in clinical development and central nervous system pharmacology at Glaxo Wellcome, where he led the team responsible for the successful filing of a sNDA for Lamictal, an approved anti-epileptic.